 For C-MenB vaccine has been shown to prevent invasive MenB disease in infants and control outbreaks, but the need for additional booster doses is not yet established. Studies have shown that antibody persistence and booster responses are maintained at high levels after primary vaccination in different age groups, with higher levels of antibodies to NHBA and Nader than PoE or FHBP. These data can inform decision making for optimizing vaccination strategies. This article was authored by Federico Martin and Torres, Terry Nolan, Daniela Toniato, and others.